These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35466962)

  • 1. Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine.
    Wong NS; Wong BCK; Chan JMC; Wong KH; Tsang OTY; Mok CKP; Hui DSC; Lee SS; Chan DPC
    AIDS; 2022 Jul; 36(9):1255-1264. PubMed ID: 35466962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.
    Chammartin F; Griessbach A; Kusejko K; Audigé A; Epp S; Stoeckle MP; Eichenberger AL; Amstutz A; Schoenenberger CM; Hasse B; Braun DL; Rauch A; Trkola A; Briel M; Bucher HC; Günthard HF; Speich B; Abela IA;
    AIDS; 2024 Feb; 38(2):217-222. PubMed ID: 37830908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
    Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
    J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.
    Costiniuk CT; Singer J; Lee T; Galipeau Y; McCluskie PS; Arnold C; Langlois MA; Needham J; Jenabian MA; Burchell AN; Samji H; Chambers C; Walmsley S; Ostrowski M; Kovacs C; Tan DHS; Harris M; Hull M; Brumme ZL; Lapointe HR; Brockman MA; Margolese S; Mandarino E; Samarani S; Vulesevic B; Lebouché B; Angel JB; Routy JP; Cooper CL; Anis AH;
    AIDS; 2023 Oct; 37(12):F25-F35. PubMed ID: 37534695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.
    Woldemeskel BA; Karaba AH; Garliss CC; Beck EJ; Aytenfisu TY; Johnston TS; Laeyendecker O; Cox AL; Blankson JN
    AIDS; 2022 Jul; 36(9):1315-1317. PubMed ID: 35833684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
    Chammartin F; Kusejko K; Pasin C; Trkola A; Briel M; Amico P; Stoekle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Mueller NJ; Rauch A; Koller MT; Günthard HF; Bucher HC; Speich B; Abela IA;
    AIDS; 2022 Aug; 36(10):1465-1468. PubMed ID: 35876706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study.
    Spinelli MA; Peluso MJ; Lynch KL; Yun C; Glidden DV; Henrich TJ; Deeks SG; Gandhi M
    Clin Infect Dis; 2022 Aug; 75(1):e916-e919. PubMed ID: 34864962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    Xu X; Vesterbacka J; Aleman S; Nowak P;
    AIDS; 2022 Mar; 36(3):479-481. PubMed ID: 35084386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
    Vergori A; Cozzi-Lepri A; Tavelli A; Mazzotta V; Azzini AM; Gagliardini R; Mastrorosa I; Latini A; Pellicanò G; Taramasso L; Ceccherini-Silberstein F; Giannella M; Tacconelli E; Marchetti G; Monforte AD; Antinori A;
    Int J Infect Dis; 2024 Jul; 144():107065. PubMed ID: 38643867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021.
    Kwok SL; Cheng SM; Leung JN; Leung K; Lee CK; Peiris JM; Wu JT
    Euro Surveill; 2022 Jan; 27(2):. PubMed ID: 35027105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.